Compositions and methods for treating hypertension by modulating endocrine activity
Disclosed herein are compounds and ligands, and compositions formed therewith, that modulate seminal endocrine factors that control blood pressure and, thereby, treat hypertension. Also disclosed herein are methods for using the compositions to treat hypertension and disorders associated therewith.
1. A method for modulating blood pressure of a patient, comprising:
providing a composition comprising a delivery medium, propionic acid and butyrate, said propionic acid comprising an EC 50 value in the range of from about 0.05 μM to about 0.5 μM, said butyrate comprising an EC 50 value in the range of from about 0.01 μM to about 0.3 μM,
said composition adapted to induce activation of at least one olfactory receptor selected from the group consisting of olfactory receptor family 51 subfamily E member 1 (OR51E1), olfactory receptor family 51 subfamily E member 2 (OR51E2), free fatty acid receptor 2 (FFAR2), free fatty acid receptor 3 (FFAR3) and hydroxycarboxylic acid receptor 2 (GPR109A) in vivo; and
delivering in the range of from about 1.0 mg/kg to about 50.0 mg/kg of said composition to said patient, wherein secretion of at least one vasodilation inducing endocrine factor is induced in vivo and, thereby, vasodilation of said patient is effectuated.
2. The method of claim 1 , wherein said at least one vasodilation inducing endocrine factor comprises an endocrine factor selected from the group consisting of serotonin (5-HT), secretin, prostaglandin E 2 and vasoactive intestinal protein (VIP).
3. The method of claim 1 , wherein said delivery medium comprises glycerin-based water.
4. The method of claim 3 , wherein in the range of from about 5.0 mg/kg to about 25.0 mg/kg of said composition is delivered to said patient.
5. A method for modulating blood pressure of a patient, comprising:
providing a composition comprising a delivery medium, propionic acid and butyrate, said propionic acid comprising an EC 50 value in the range of from about 0.05 μM to about 0.5 μM, said butyrate comprising an EC 50 value in the range of from about 0.01 μM to about 0.3 μM,
said composition adapted to induce at least 50% activation of olfactory receptor family 51 subfamily E member 1 (OR51E1), olfactory receptor family 51 subfamily E member 2 (OR51E2), free fatty acid receptor 2 (FFAR2), free fatty acid receptor 3 (FFAR3) and hydroxycarboxylic acid receptor 2 (GPR109A) in vivo; and
delivering in the range of from about 1.0 mg/kg to about 50.0 mg/kg of said composition to said patient, wherein secretion of serotonin (5-HT), secretin, prostaglandin E 2 and vasoactive intestinal protein (VIP), and attenuated secretion of nuclear factor κ-B (NK-κB) and NADPH Oxidases (NOXs) are induced in vivo and, thereby, vasodilation of said patient is effectuated.
6. The method of claim 5 , wherein said delivery medium comprises glycerin-based water.
7. The method of claim 6 , wherein in the range of from about 5.0 mg/kg to about 25.0 mg/kg of said composition is delivered to said patient.